Actavis launches generic Casodex in Western Europe
This article was originally published in Scrip
Executive Summary
Actavis has launched the first generic versions ofAstraZeneca's anticancer anti-androgen, Casodex (bicalutamide), in the UK, Germany and France. Casodex's patent protection expired on July 8th in the UK and July 9th in Germany and France, Actavis said, and distribution of the product has already started. 50mg tablets of bicalutamide will be available from Actavis in all three markets, while a 150mg tablet will also be available in the UK. Casodex is the world's leading aromatase inhibitor, with global sales last year of $1.34 billion, up by 6% on sales in 2006. Actavis has already launched generic bicalutamide in the Czech Republic, Slovakia, Poland and Iceland.